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In Brief
How the immune system uses
evolutionarily conserved signaling
pathways involved in tissue development
to orchestrate wound repair following
injury has remained largely unresolved.
Here, Minutti et al. show that the
macrophage-derived EGFR ligand
Amphiregulin induces local TGF-b
activation and thereby the differentiation
of tissue-resident pericytes.
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The epidermal growth factor receptor ligand Amphir-
egulin has a well-documented role in the restoration
of tissue homeostasis after injury; however, the
mechanism by which Amphiregulin contributes to
wound repair remains unknown. Here we show that
Amphiregulin functioned by releasing bioactive
transforming growth factor beta (TGF-b) from latent
complexes via integrin-aV activation. Using acute
injury models in two different tissues, we found that
by inducing TGF-b activation on mesenchymal stro-
mal cells (pericytes), Amphiregulin induced their dif-
ferentiation into myofibroblasts, thereby selectively
contributing to the restoration of vascular barrier
functionwithin injured tissue. Furthermore, we identi-
fied macrophages as a critical source of Amphiregu-
lin, revealing a direct effector mechanism by which
these cells contribute to tissue restoration after acute
injury. Combined, these observations expose a so far
under-appreciatedmechanismof howcells of the im-
mune system selectively control the differentiation
of tissue progenitor cells during tissue repair and
inflammation.
INTRODUCTION
Maintenance of tissue integrity is a critical process in the devel-
opment and survival of an organism. Disruption of tissue homeo-
stasis through infections or injury induces a local immune
response that facilitates a tissue repair process that in many re-Immunity 50, 645–654, M
This is an open access article undspects resembles the process of organ development. During this
process of wound repair, cells of the immune system support cell
proliferation and differentiation in a well-orchestrated manner,
ensuring successful tissue regeneration and wound closure
(Aurora and Olson, 2014; Martin and Leibovich, 2005; Mescher
and Neff, 2005).
Accordingly, the immune system has adapted evolutionarily
conserved signaling pathways, such as, for instance, transform-
ing growth factor beta (TGF-b) and the epidermal growth factor
receptor (EGFR). These signal transduction pathways play
critical roles during both physiological processes: tissue devel-
opment and wound repair. However, the exact role of these
pathways, the cellular triggers, and their interactions during
tissue regeneration remain incompletely understood. This is, in
part, due to the fact that both pathways have exceptionally pleio-
tropic functions, but it is also due to the wide variety of different
ligands that bind to these two receptors and whose activity is
strongly influenced by factors such as the nature of ligand bind-
ing to the receptor (Freed et al., 2017), the state of local inflam-
mation, and the state of the receiving cell (Massague´, 2000).
In particular, the EGFR ligand Amphiregulin, expressed under
inflammatory conditions by several types of leukocytes, has
emerged as a critical player in immunity, inflammation, and tis-
sue repair (Berasain and Avila, 2014; Zaiss et al., 2015). In
numerous experimental settings, the delivery of recombinant
Amphiregulin (rAREG) enhances the process of tissue repair af-
ter injury (Arpaia et al., 2015; Burzyn et al., 2013; Jamieson et al.,
2013; Monticelli et al., 2011). Nevertheless, the underlyingmech-
anism that underpins the contribution of Amphiregulin to tissue
repair and how it interacts with other known mediators of this
process to facilitate wound healing remain largely unexplored.
We therefore sought to determine the mechanism by which
Amphiregulin contributes to the restoration of tissue homeo-
stasis after acute tissue injury. Thereby, we have uncovered aarch 19, 2019 ª 2019 The Authors. Published by Elsevier Inc. 645
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Amphiregulin Contributes to the
Restoration of Blood Barrier and Lung
Function
WTand Areg/mice were either left uninfected or
infected with N. brasiliensis and either injected
with 5 mg of rAREG at days 1, 2, and 3 post
infection or left untreated.
(A) Representative H&E staining and histological
analysis of lung tissue at different dpi (days post
infection).
(B) Oxygen saturation in the blood at different dpi.
(C) Number of red blood cells in the BAL (bron-
choalveolar lavage).
(D) Extravasation of Evans blue into the alveolar
space as a marker of vascular permeability.
(E) mRNA (Acta2) and protein expression of the
aSMA at 4 dpi were evaluated by qRT-PCR
and WB.
All data are representative of at least two indepen-
dent experiments (mean ± SEM); results for indi-
vidual mice are shown as dots. See also Figure S1.mechanism by which EGFR-mediated signaling regulates local
TGF-b activity. We found that Amphiregulin expression induced
the integrin-aV-mediated conversion of latent TGF-b into its
bioactive form and, in turn, promoted the differentiation of tissue
progenitor cells. After acute tissue injury, this mechanism
enabled tissue-resident macrophage-derived Amphiregulin to
induce TGF-b activation and the differentiation of pericytes into
collagen-producing myofibroblasts, thereby causing rapid tis-
sue re-vascularization and wound healing.
RESULTS
Amphiregulin Contributes to the Restoration of Blood
Vessel Integrity and Lung Function
To determine the physiological relevance of endogenously ex-
pressed Amphiregulin during acute wound healing, we utilized a
model of acute lung injury caused by infection with the nematode
Nippostrongylus brasiliensis (Chen et al., 2012; Minutti et al.,
2017b; Sutherland et al., 2014). After inoculation, N. brasiliensis
larvae migrate through the lungs, causing damage to the epithe-
lium and vasculature, which leads to loss of lung function and a
drop in blood oxygen saturation (Nieves et al., 2016). After
N. brasiliensis infection, Areg/ and C57BL/6 wild-type (WT)
mice showed a similar extent of lung damage (Figure 1A) and
loss of lung function (Figure 1B). Also, the influx of leukocytes
into the lungs was similar in composition and number (Fig-
ure S1A), and the migration of Nippostrongylus larvae through
the lungs into the intestine was not affected by Amphiregulin defi-
ciency (Figure S1B). However, in the recovery phase, Areg/
mice presented a significantly delayed restoration of lung func-
tion in comparison to WTmice (Figure 1B). This delay in recovery
was associated with a diminished restoration of blood vessel
integrity as measured by the number of red blood cells and the
extravasation of Evans blue dye in the bronchoalveolar lavage
(Figures 1C and 1D). Furthermore,Areg/mice had a diminished646 Immunity 50, 645–654, March 19, 2019transcriptional expression of collagen 1a
types I and III (Figure S1C) and aSMA, a
marker of myofibroblast differentiation(Figure 1E), on day 4 post infection. Importantly, all the features
of Amphiregulin deficiency could be fully reversed by injection
of recombinant Amphiregulin (rAREG) (Figures 1B–1E).
Similarly, in amodel of acute liver damage induced by injection
of the hepatotoxin carbon tetrachloride (CCl4), Areg
/ and
C57BL/6 WT mice showed a similar severity of liver damage
and overall recovery after CCl4 injection (Figures S1D and
S1E); however, Areg/ mice showed a significantly delayed
restoration of blood barrier function in the liver, similar to results
in the lungs (Figure S1F).
These data suggest that, after acute tissue damage, Amphire-
gulin mainly contributes to the process of wound healing by
enhancing the restoration of vasculature barrier function.
Macrophage-Derived Amphiregulin Contributes to the
Restoration of Vascular Integrity
To investigate the physiologically relevant cellular source of Am-
phiregulin after N. brasiliensis infection, we first established a
mouse strain with an Amphiregulin deficiency specifically within
hematopoietic cells (Vav1-cre 3 Aregfl/fl). By infecting this strain
with N. brasiliensis larvae, we found a substantially delayed re-
covery of lung and blood barrier function, suggesting that the
main source of Amphiregulin contributing to the restoration of
the blood barrier function must be of hematopoietic origin (Fig-
ures S1G–S1K). Because T cells have been shown to produce
Amphiregulin (Arpaia et al., 2015; Burzyn et al., 2013; Zaiss
et al., 2006), we assessed lung repair after N. brasiliensis infec-
tion in mice that lack T and B cells (Rag1/). Because the
absence of an adaptive immune system did not influence the
extent of blood extravasation in Rag1/ mice compared to
that of WT mice (Figure S1L), we conclude that mainly innate im-
mune cells produce Amphiregulin that contributes to the process
of wound healing after N. brasiliensis infection.
To investigate the innate cell population that produces Am-
phiregulin after tissue injury in more detail, we injected brefeldin
Figure 2. Macrophage-Derived Amphiregu-
lin Contributes to the Restoration of Blood
Barrier Function
WT and Aregflox/flox3 Lyz2cremice were either left
uninfected or infected with N. brasiliensis.
(A) Absolute number of Amphiregulin expressing
leukocytes following brefeldin A injection and
intracellular cytokine staining of whole lung lysates
at 3 dpi.
(B) Oxygen saturation in the blood at different dpi.
(C) Number of red blood cells in the BAL.
(D) Extravasation of Evans blue into the alveolar
space.
(E) Expression of aSMA and collagen a1 type-I-
and type-III-encoding genes at 4 dpi were evalu-
ated.
All data are representative of at least two inde-
pendent experiments (mean ± SEM); results for
individual mice are shown as dots. See also Fig-
ure S2.A on day 3 after N. brasiliensis infection. Injection of brefeldin A
prevents protein secretion; thus, subsequent Amphiregulin
staining in lung cell suspensions allowed us to reliably detect
Amphiregulin expression by different hematopoietic cell types
in vivo (Figure S2A). Although we detected Amphiregulin expres-
sion by several types of innate cells, the induction of Amphiregu-
lin expression was most pronounced in alveolar macrophages
(Figures 2A, S2B, and S2C), which were also one of the most
frequent types of leukocytes appearing in the lungs over the first
three days of infection (Figure S2B). Thus, although regulatory T
(Treg) cells, eosinophils, and ILCs also produced considerable
amounts of Amphiregulin (Figure S2C), macrophages appeared
to be a major source of Amphiregulin in infected lungs (Figures
2A, S2B, and S2C). We therefore generated a mouse strain
with a myeloid-specific deficiency of Amphiregulin (Lyz2cre 3
Aregfl/fl), which showed an alveolar-macrophage-specific lack
of Amphiregulin expression (Figure S2D). After N. brasiliensis
infection, Lyz2cre3 Aregfl/fl mice showed a similar worm burden
and an increase in inflammatory infiltrates indistinguishable from
that seen in WT mice (Figures S2E and S2F). However, in com-Iparison to WT mice, the genetically modi-
fied mouse strain showed an impaired
restoration of lung function and blood
vessel integrity (Figures 2B–2D) after
N. brasiliensis infection and impaired in-
duction of collagen 1a type I and type III
and aSMA expression (Figure 2E).
To ensure that Amphiregulin deficiency
does not impair the functionality of alve-
olar macrophages during lung repair,
we tested the ability of alveolar macro-
phages from Lyz2cre 3 Aregfl/fl mice to
acquire an alternative activation program
and to proliferate after N. brasiliensis
infection. Because we could not find any
substantial differences between Amphire-
gulin-deficient and WT macrophage pro-
liferation and differentiation (Figure S2G),we concluded that Amphiregulin is not contributing to these
processes.
Moreover, comparable to our observations in the lungs,
Lyz2cre3Aregfl/flmice showed, in comparison toWT littermates,
a delayed restoration of blood vessel integrity after CCl4-induced
liver damage, despite experiencing similar severity of liver dam-
age and overall recovery after CCl4 injection (Figures S2H–S2J).
These data suggest that macrophage-derived Amphiregulin
has no effect on alveolar macrophages themselves but directly
contributes to wound repair by enhancing the restoration of
blood vessel integrity after N. brasiliensis infection.
Extracellular ATP Is an Important Stimulus Inducing
Amphiregulin Expression in Macrophages
Having identified alveolar macrophages as critical sources of
Amphiregulin at the initiation of tissue repair after acute lung
injury, we wanted to identify the factors that induce its expres-
sion. Previous studies have shown that several damage-
associated molecular patterns (DAMPs), such as alarmins (inter-
leukin [IL]-33, IL-25, and TSLP [thymic stromal lymphopoietin]) ormmunity 50, 645–654, March 19, 2019 647
Figure 3. Sensing Extracellular ATP from Tissue Necrosis Drives
Amphiregulin Expression by Macrophages
(A) In vitro differentiated bone marrow derived macrophages were treated as
indicated. Expression of Amphiregulin-encoding gene was measured 10 h
after treatment.
(B) WT andMyd88/3 Trif/mice were either left uninfected or infected with
N. brasiliensis.
Percentage of Amphiregulin-expressing (cell surface and intracellular after i.v.
injection of brefeldin A) macrophages at 3 dpi (upper panel), number of red
blood cells in the BAL (middle panel), and extravasation of Evans blue into the
alveolar space at 4 dpi (lower panel).
(C) Alveolar and peritoneal macrophages were purified by adherence and then
treated with ATP. Expression of Amphiregulin-encoding gene was measured
10 h after treatment.
(D) WT mice were either left uninfected or infected with N. brasiliensis
and either received two individual doses of Apyrase at day 1 post-infection,
or did not. Number and percentage of Amphiregulin expressing alveolar
macrophages following brefeldin A injection and intracellular cytokine staining
of lung lysate at 2 dpi.
All data are representative of at least two independent experiments (mean ±
SEM); results for individual mice are shown as dots. See also Figure S3.extracellular ATP, can induce Amphiregulin expression in leuko-
cytes (Zaiss et al., 2015). Therefore, to test their capacity to
induce Amphiregulin expression in macrophages, we differenti-
ated bone-marrow-derived macrophages (BMDMs) in vitro and
measured Areg mRNA expression upon treatment with these
molecules. We also treated BMDMs with factors that induce648 Immunity 50, 645–654, March 19, 2019classical (lipopolysaccharide [LPS] and interferon [IFN]-g) and
alternative (IL-4 and IL-13) activation of macrophages to test if
Amphiregulin expression by macrophages was associated with
their activation. As shown in Figure 3A, we observed that mainly
ATP and LPS, but not IL-33, induced Amphiregulin expression.
To confirm these findings in vivo, we measured Amphiregulin
expression and the process of lung repair after N. brasiliensis
infection in WT and Myd88/ 3 Trif/ mice, a mouse strain
lacking the ability to propagate the signaling caused by LPS
and IL-33. In line with the fact that the overall influx of leukocytes
into the lungs of infected mice was not affected (Figure S3A), the
induction of Amphiregulin expression by macrophages after
N. brasiliensis infection was also not impaired in Myd88/ 3
Trif/ mice (Figure 3B). Accordingly, Myd88/ 3 Trif/ mice
recovered the vascular barrier function in a comparable way to
WT mice 4 days after infection (Figure 3B). These data strongly
suggest that neither LPS nor IL-33 is involved in the induction
of Amphiregulin expression by alveolar macrophages.
To determine the capacity of extracellular ATP to induce
Amphiregulin expression in tissue-resident macrophages, we
isolated macrophages from the alveolar space and the perito-
neal cavity and exposed them to ATP. Similar to BMDMs, perito-
neal and alveolar macrophages readily induced Amphiregulin
expression upon ATP treatment (Figure 3C).
Finally, to test the impact of ATP sensing by alveolar macro-
phages during N. brasiliensis infection, we depleted extracellular
ATP by treating WT mice with Apyrase at day 1 post infection,
when the infective larvae start colonizing the lungs. Although
the overall influx of leukocytes into the lungs of infected mice
and the migration of worm larvae through the lungs were not
affected (Figures S3B and S3C), we observed that a day after
Apyrase delivery, Amphiregulin expression by alveolar macro-
phages was significantly diminished (Figure 3D).
These findings strongly suggest that sensing extracellular ATP
allows alveolar macrophages to recognize tissue damage and
induce the expression of Amphiregulin, allowing for a rapid repair
of the vascular barrier function.
Amphiregulin Induces the Activation of Integrin-aV and
Consequently the Release of Bioactive TGF-b
Having established the source of Amphiregulin, we wanted to
know the downstream effector mechanisms that underpin Am-
phiregulin’s effects on vascular repair. Mesenchymal stromal
cells, or so-called pericytes, are a major myofibroblast precur-
sor cell type in the lungs and liver (Henderson et al., 2013)
known to promote integrity of blood vessels (Lindahl et al.,
1997). Myofibroblast differentiation under inflammatory condi-
tions is TGF-b driven (Henderson et al., 2013). TGF-b is
secreted in the form of a latent, inactive protein complex and
is locally released into its bioactive form, for instance, in an in-
tegrin-aV-mediated step (Gleizes et al., 1997; Henderson and
Sheppard, 2013; Munger et al., 1999). Because the delayed
restoration of lung function in Areg/ mice was directly associ-
ated with a diminished expression of the myofibroblast differen-
tiation marker aSMA (Acta2) (Figure 1E), we hypothesized that
Amphiregulin may induce the release of bioactive TGF-b by
activating integrin-aV-containing integrin complexes. To test
this hypothesis, we isolated primary platelet-derived growth
factor receptor-b (PDGFRb)-expressing pericytes and exposed
Figure 4. Amphiregulin InducesPericyteDif-
ferentiation by Releasing Bioactive TGF-b
via Integrin-aV
(A and B) Primary lung pericytes were cultured in
the presence or absence of 100 ng/ml Amphir-
egulin (A), then incubated with latent TGF-b in the
presence and absence of PLCg inhibitor U-73122
(B) and analyzed for LAPbinding by flowcytometry.
(C–F) After 24 h of treatment, the release of bioac-
tive TGF-b (upper panel), as well as their differen-
tiation into myofibroblasts (lower panels), was
determined in the presence or absence of inhibi-
tors for the EGFR (Gefitinib) (C), PLCg inhibitor
(U-73122) (D), integrin-aV (CWHM-12 and its inac-
tive control enantiomer CWHM-96) (E), or TGF-b-R
(ALK5i) (F).
(G) The induction of aSMA in treated pericytes was
also evaluated at the protein level by western blot
analysis.
(H) Differentiation of primary lung pericytes into
myofibroblasts following o/n co-culture with (left
graph) or o/n exposure to supernatants derived
from (right graph) alveolar macrophages isolated
from infected or uninfected WT or Areg-/- mice.
All data are representative of at least two inde-
pendent experiments except for (B)–(D) (mean ±
SEM); results for preparations from individual mice
are shown as dots. See also Figure S4.them to latent TGF-b in the presence and absence of rAREG.
We found that although rAREG treatment did not increase the
transcription or the cell-surface expression of integrin-aV on
cultured pericytes (Figures S4A and S4B), it enhanced the bind-
ing of the TGF-b latent associated protein (LAP) to pericytes
(Figure 4A), a process that could be fully reverted by the addi-
tion of an integrin-aV-blocking antibody RMV-7 (Figure 4A).
These data suggest that rAREG induced the activation of integ-
rin-aV-containing integrin complexes on pericytes.
The activation of integrin-aV complexes by Amphiregulin reca-
pitulated all the hallmarks of an ‘‘inside-out’’ activation of integrins
triggered by other growth factors (Shattil et al., 2010). In this pro-
cess, the growth factor induces sustained phospholipase-Cg
(PLCg) signaling that leads to cytoskeleton rearrangements
within the cell, which then pull the two integrin subunits apartIand, in this way, open their structure on
the cell surface (Shattil et al., 2010). There-
fore, to test whether rAREG induces the
‘‘inside-out’’ activation of integrin-aV, we
repeated the latter experiment in the pres-
ence of the PLCg inhibitor U-73122. As
shown in Figure 4B, such treatment fully
prevented the binding of LAP to integrin-
aV, strongly suggesting that Amphiregulin
induces the activation of integrin-aV via an
‘‘inside-out’’-mediated mechanism.
Based on these findings, we further
queried whether the rAREG-induced acti-
vation of integrin-aV may also induce the
release of bioactive TGF-b and in this
way induce the differentiation of pericytes
into myofibroblasts. In accordance withsuch a hypothesis, we found that, although rAREG did not influ-
ence the secretion of total TGF-b from primary pericytes (Fig-
ure S4C), it induced the release of bioactive TGF-b from its latent
form (upper panel, Figures 4C–4F; Figure S4D). The release of
bioactive TGF-b was prevented by the addition of the EGFR in-
hibitor Gefitinib (Figure 4C) and was absent in cultures of primary
pericytes derived from Pdgfrb-cre3 Egfrfl/fl mice (Figure S4D), a
mouse strain with a pericyte-specific deletion of the EGFR (Hen-
derson et al., 2013). Furthermore, the blockade of PLCg signaling
(Figure 4D, upper panel) or of integrin-aV by CWHM-12 (Hender-
son et al., 2013) (Figure 4E, upper panel), but not of TGF-b-RI by
an ALK5 inhibitor (Figure 4F, upper panel), blocked the release of
bioactive TGF-b by rAREG-treated pericytes.
In accordance with rAREG release of bioactive TGF-b, we
found that the addition of rAREG also induced themmunity 50, 645–654, March 19, 2019 649
Figure 5. r TGF-b Restores Tissue Repair in
Areg–/– Mice
(A–C) WT or Areg/ mice were either left unin-
fected or infectedwithN. brasiliensis.Ondays 1, 2,
and 3 pi, mice were treated with 5 mg of rTGFb or
left untreated. (A) Oxygen saturation in the blood at
different dpi, (B) number of red blood cells in the
BAL, and (C) extravasation of Evans blue into the
alveolar space at 4 dpi were evaluated.
(D–G) Egfrflox/flox or Egfrflox/flox 3 Pdgfrb-cre mice
were either left uninfected or infected with
N. brasiliensis. On days 1, 2, and 3 pi, mice were
treated with 5 mg of either rAREG or rTGFb or left
untreated. (D) Oxygen saturation in the blood at
different dpi, (E) number of red blood cells in the
BAL, (F) extravasation of Evans blue into the
alveolar space, and (G) expression of the aSMA
and collagen a1 types I and III were evaluated at 4
dpi.
Data represent mean ± SEM; results for individual
mice are shown as dots. See also Figure S5.differentiation of pericytes into myofibroblasts (lower panel,
Figures 4C–4F; Figure S4D), which was an effect fully reverted
by the addition of the EGFR inhibitor Gefitinib (Figure 4C), the
PLCg signaling inhibitor U-73122 (Figure 4D), the integrin-aV
inhibitor CWHM-12 (Figure 4E, lower panel), or TGF-b-RI inhi-
bition (Figure 4F, lower panel) and which was absent in
cultures of pericytes derived from Pdgfrb-cre 3 Egfrfl/fl mice
(Figure S4D). Importantly, pericytes from Pdgfrb-cre 3 Egfrfl/fl
mice remained responsive to TGF-b (Figure S4D), further con-
firming our observations using pharmacological inhibitors
of EGFR.
Furthermore, to demonstrate that the quantification of Acta2
mRNA was a bona fide surrogate measurement of the differ-
entiation of pericytes into myofibroblasts, we performed
immunoblot analysis of treated pericytes with anti-aSMA spe-
cific antisera. As shown in Figure 4G, the expression of aSMA
in isolated pericytes significantly increased upon exposure to
rAREG or recombinant (r)TGF-b, formally demonstrating that
Amphiregulin induces the differentiation of pericytes into
myofibroblasts.
Finally, in order to formally demonstrate that macrophage-
derived Amphiregulin can also induce the differentiation of peri-650 Immunity 50, 645–654, March 19, 2019cytes, we isolated alveolar macrophages
from N. brasiliensis-infected mice (WT
and Areg/) and co-cultured them with
primary pericytes. As shown in Figure 4H,
the co-culture of alveolar macrophages
derived from WT mice, but not from
Areg/ mice, induced the differentiation
of pericytes into myofibroblasts. Also,
the supernatants of overnight-cultured
alveolar macrophages from infected
WT mice, but not from Areg/ mice,
induced the differentiation of pericytes
into myofibroblasts.
Combined, these data reveal a mecha-
nism by which Amphiregulin induces the
activation of integrin-aV on pericytes,causing the local release of bioactive TGF-b from latent TGF-b
and thus their differentiation into myofibroblasts.
rTGF-b Reverts the Effects of Amphiregulin and
Pericyte-Specific EGFR Deficiency In Vivo
Next, we sought to reveal the physiological relevance of themech-
anism we had found in vitro. In accordance with our previous
observation that Amphiregulin mediates TGF-b activation, we
found thatN. brasiliensis-infected Areg/mice show, in compar-
ison to WT C57BL/6 counterparts, a diminished expression of
pSMAD3, the main mediator of TGF-b signaling (Figure S4E).
This suggests that Amphiregulin in vivo also contributes to the
release of bioactive TGF-b. To test the link between Amphiregulin
and TGF-b, we injected rTGF-b into N. brasiliensis-infected
Areg/ mice. As shown in Figures 5A–5C, the injection of
rTGF-b fully reverted the deficiency of Areg/ mice in the resto-
ration of lung function and blood vessel integrity.
To dissect this mechanism further, we analyzed Pdgfrb-cre 3
Egfrfl/fl mice, amouse strain with a pericyte-specific deficiency of
EGFR expression. At steady state, Pdgfrb-cre 3 Egfrfl/fl mice
showed no reduced transcriptional expression of Pdgfrb in com-
parison to WT controls, and thus we conclude that EGFR
Figure 6. Amphiregulin Restores Blood Bar-
rier Function via Pericyte-Specific Activation
of Integrin-aV Complexes
(A and B) WT mice were infected with N. brasiliensis
or left uninfected, and minipumps containing the
integrin-aV inhibitor CWHM12 were inserted sub-
cutaneously 3 days prior to infection. Mice were
treatedwith 5 mg of either rAREG or rTGFb 1, 2, and 3
dpi. (A) Number of red blood cells in the BAL and (B)
extravasation of Evans blue into the alveolar space
were evaluated 4 dpi.
(C–E) Igtavflox/flox and Igtavflox/flox3 Pdgfrb-cremice
were infected with N. brasiliensis or left uninfected.
(C) Oxygen saturation in the blood at different dpi.
(D) Number of red blood cells in the BAL and (E)
extravasation of Evans blue into the alveolar space
were evaluated 4 dpi.
Data represent mean ± SEM; results for individual
mice are shown as dots. See also Figure S6.ablation on pericytes did not affect the development or survival
of this cell population (Figure S5A). Nevertheless, when mice
were infected with N. brasiliensis, we found that, similar to
Areg/ mice, Pdgfrb-cre 3 Egfrfl/fl mice also showed a dimin-
ished restoration of lung function (Figure 5D) and blood vascula-
ture integrity (Figures 5E and 5F). Also, aSMA and collagen gene
expression on day 4 post infection was diminished in compari-
son to WT mice (Figure 5G). Pdgfrb-cre 3 Egfrfl/fl mice showed
a similar influx of leukocytes into the lungs (Figure S5B), a com-
parable alveolar damage (Figure S5C), and a similar worm
burden (Figure S5D) to WT mice. Furthermore, similar
results were found in the liver, with the restoration of blood
barrier function being selectively delayed after CCl4-induced
damage in Pdgfrb-cre 3 Egfrfl/fl mice compared to WT litter-
mates, despite a similar extent of inflammation and necrosis (Fig-
ures S5E–S5H).
Moreover, although the injection of rTGF-b into N. brasiliensis-
infected Pdgfrb-cre3 Egfrfl/fl mice (Figures 5D–5G) fully restored
their lung function, blood barrier integrity, and myofibroblast dif-
ferentiation on day 4 post infection, the administration of rAREG
did not revert this phenotype in Pdgfrb-cre 3 Egfrfl/fl mice (Fig-
ures 5D–5F).
Taken together, these data demonstrate that Amphiregulin
functions upstream of TGF-b in the differentiation of pericytes
into myofibroblasts during acute tissue damage.
Amphiregulin-Induced Integrin-aV Activation Promotes
Vascular Repair
To address the role of Amphiregulin-induced integrin-aV activa-
tion in the restoration of lung function duringN. brasiliensis infec-
tion, we inserted mini pumps containing the integrin-aV inhibitor
CWHM-12 into C57BL/6 WT mice prior to N. brasiliensis infec-tion. We found that treatment with the in-
tegrin-aV inhibitor CWHM12 had no effect
on the increase in inflammatory infiltrates
into the lungs or the migration of worms
into the intestine (Figures S6A and S6B).
Nevertheless, mice treated with the integ-
rin-aV inhibitor CWHM12 showed a dimin-ished restoration of blood barrier function after N. brasiliensis
infection (Figures 6A and 6B). This effect could fully be reverted
by the administration of rTGF-b but not by rAREG (Figures 6A
and 6B). These data clearly demonstrate that Amphiregulin ef-
fects occur upstream of integrin-aV activation.
Finally, to directly demonstrate the involvement of integrin-aV
on pericytes during vascular repair, we generated pericyte-
specific integrin-aV-deficient mice (Pdgfrb-cre 3 Itgav
fl/fl) and
infected these with N. brasiliensis larvae. As shown in Figures
6C–6E, pericyte-specific deficiency of integrin-aV directly repro-
duced the effects of systemic CWHM-12 delivery during
N. brasiliensis infection—again showing a delay in the recovery
of lung function and vascular repair, despite having a similar
influx of leukocytes into the lungs and wormmigration into the in-
testine (Figures S6C and S6D).
These experiments demonstrate that in vivo Amphiregulin also
contributes to the restoration of tissue integrity by inducing in-
tegrin-aV-mediated TGF-b release specifically on pericytes.
DISCUSSION
Our data reveal amechanism bywhich Amphiregulin induces the
activation of integrin-aV complexes on pericytes and, in this way,
induces the local release of bioactive TGF-b. This in turn induces
their differentiation into collagen-producing myofibroblasts,
which critically contributes to the restoration of vascular integrity
in injured tissues.
This link between Amphiregulin-induced EGFR signaling and
TGF-bactivationmayexplain, in addition to its role inwoundheal-
ing, several formerly described effects associated with Amphire-
gulin expression. Amphiregulin has been associated with tissue
fibrosis (Perugorria et al., 2008), regulatory T-cell-mediatedImmunity 50, 645–654, March 19, 2019 651
immune regulation (Zaiss et al., 2013), and tumor growth (Kham-
bata-Ford et al., 2007; Li et al., 2010; Tinhofer et al., 2011). Asall of
these processes are strongly influenced by TGF-b-induced
signaling (Li et al., 2006), our data suggest that, in these situations
also, Amphiregulin may function by inducing the activation of
locally expressed latent TGF-b. To target TGF-b directly in a
therapeutic setting is currently strongly hindered by its house-
keeping function, for instance, due to its role in heart muscle
homeostasis. However, TGF-b can be activated in different
ways, and the inflammatory activation is mainly mediated by
integrin-aV activation (Henderson and Sheppard, 2013). There-
fore, our finding that Amphiregulin regulates TGF-b function un-
der inflammatoryconditionsmaypropose targetingAmphiregulin
activity as an attractive alternative therapeutic approach in the
context of tumor therapy or chronic inflammation-associated
fibrotic diseases.
Our findings furthermore elaborate a previously unrecognized
way by which macrophages contribute to wound healing. It is
well-established that macrophages contribute to the process
of wound healing by removing cell debris and the release of
growth factors that, for example, stimulate angiogenesis or fibro-
blast replication and subsequently dampen inflammation (Min-
utti et al., 2017c; Wynn et al., 2013). Our data now show that
by responding to the breach of barrier function and controlling
the local release of bioactive TGF-b, macrophages also control
the differentiation of local tissue precursor cells. This finding
dovetails with previous studies demonstrating that alveolar mac-
rophages in particular play an essential role in limiting acute tis-
sue damage during experimental helminth infection (Chen et al.,
2012; Minutti et al., 2017b) and reveals an additional function for
a cell type, optimally located to function as a sentinel of tissue
injury.
This specific location of macrophages may also explain the
specific role macrophage-derived Amphiregulin plays during
the restoration of blood vessel integrity. Several types of leuko-
cytes have previously been described to express Amphiregulin
and to contribute to wound healing (Arpaia et al., 2015; Burzyn
et al., 2013; Jamieson et al., 2013; Monticelli et al., 2011); how-
ever, in our case, macrophage-derived Amphiregulin specif-
ically appears to play a central role. One potential explanation
could be based on the fact that, soon after injury, macro-
phages are drawn to wound blood vessels (Gurevich et al.,
2018). In this way, macrophages are optimally situated to
sense the release of ATP from necrotic cells and to locally pro-
duce physiologically critical amounts of Amphiregulin, which
then induce the local activation of bioactive TGF-b and thus
the differentiation of blood-vessel-associated pericytes. In
this way, the locally expressed, macrophage-derived Amphire-
gulin can critically contribute to wound healing, whereas Am-
phiregulin produced by other leukocytes at other sites within
the lungs might be of less importance for the restoration of
blood vessel integrity.
Furthermore, the cross-talk between EGFR and TGF-b
described here substantially contributes to our understanding
of how the function of the pleiotropic cytokine TGF-b is regu-
lated. A cross-talk between EGFR and TGF-b signaling has
been proposed before. However, so far these studies have
focused exclusively on the high-affinity EGFR ligand EGF,
which interferes with TGF-b intra-cellular signaling and counter-652 Immunity 50, 645–654, March 19, 2019acts its functioning (Lo et al., 2001; Massague´, 2000), thereby
inducing the proliferation and preventing the differentiation of
tissue stem cells (Basak et al., 2017). In contrast to EGF, Am-
phiregulin is a low-affinity EGFR ligand (Berasain and Avila,
2014) and as such induces a tonic signal via the EGFR (Freed
et al., 2017). Accordingly, Amphiregulin does not induce recep-
tor internalization (Stern et al., 2008) but preferentially induces
PLCg signaling via the phosphorylation of Tyr992 (Gilmore
et al., 2008; Minutti et al., 2017a). It is well established that
the induction of tonic PLCg signaling by growth factors induces
integrin complex activation (Shattil et al., 2010), which in turn is
known to be a critical step in the local conversion of latent into
bioactive TGF-b (Robertson and Rifkin, 2016). Thus, in conclu-
sion, our data reveal that EGFR-mediated signaling is a key
determinant of the local functionality of TGF-b. Depending on
the quality of the EGFR-induced signals, different ligands can
either activate TGF-b (Amphiregulin induced) or block its activ-
ity (EGF induced).
Such a way to regulate TGF-b function may also resolve the
long-standing paradigm that signaling via some receptor-tyro-
sine kinases, such as NGF via the NGFR, can induce the differ-
entiation of the neural progenitor cells PC-12, whereas other
signals, such as EGF via the EGFR, can actively block their differ-
entiation (Traverse et al., 1992). So far, it has been assumed that
the qualitative difference in MAP-kinase activation (tonic versus
oscillating) is the main driver of these different physiological out-
comes (Marshall, 1995). However, our data now suggest a
possible alternative explanation for this phenomenon, i.e., that
different growth factors induce distinct intra-cellular signals
that interfere with the TGF-b signaling pathway (Lo et al., 2001)
and thereby either prevent differentiation (Basak et al., 2017) or
actively induce the activation of TGF-b, in this way inducing
the differentiation of PC-12. Further analysis of the effect of
NGF on integrin-aV activation and consecutive release of bioac-
tive TGF-b upon exposure to PC-12 cells may help to confirm
such a hypothesis.
The cross-talk between the EGFR and TGF-b unraveled in
this manuscript may also explain the selective expression of
the EGFR on tissue progenitor cells. This is by far the best stud-
ied in the situation of Lgr5-expressing intestinal stem cells.
Lgr5-expressing intestinal stem cells have a high expression
of the EGFR, which supports their proliferation and prevents
their differentiation (Basak et al., 2017). Resting, so-called
‘‘reserve’’ tissue stem cells, however, are physically removed
from the proliferating stem cell compartment; they have low
expression of the EGFR and even express the molecular
EGFR inhibitor LRIG (leucine-rich repeats and immunoglob-
ulin-like domains) (Powell et al., 2012; Wong et al., 2012).
Such active inhibition of the EGFR may function to prevent
the proliferation of these resting stem cells or, alternatively, to
prevent untimely TGF-b-induced differentiation. Under inflam-
matory conditions, however, the expression of the EGFR on
activated tissue stem cells may open a window of opportunity
for cells of the immune system to influence the fate decision
of tissue stem cells by secreting Amphiregulin, inducing their
differentiation. This mechanism could then enable inflamed tis-
sue to rapidly adjust to changes in the state of inflammation, in
this way contributing to the restoration and maintenance of tis-
sue integrity.
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Rat anti mouse CD90.2 (clone 30-H12) Biolegend 105327
Rat anti mouse c-kit (clone 2B8) Biolegend 105813
Hamster anti mouse FcεRIa (clone MAR-1) Biolegend 134309
Hamster anti mouse CD49b (clone HM ALPHA2) BD PharMingen 558759
Rat anti mouse ICAM-2 (clone 3C4 MIC2/4) Biolegend 105612
Rat anti mouse LAP (clone TW7-16B4) Biolegend 141405
Goat anti mouse amphiregulin (polyclonal) R&D Systems BAF989
Rat anti mouse FoxP3 (clone MF23) BD Biosciences 562466
Rabbit anti mouse RELMa (polyclonal) PeproTech Inc. 500-P214
Mouse anti human Ki67 (clone B56) BD Biosciences 556026
Rat anti-mouse CD51 (aV integrin) (clone RMV-7) Biolegend 104105
Phospho-Smad3 (Ser423/425) (C25A9) Rabbit mAb Cell Signaling 9520
a-Smooth Muscle Actin (D4K9N) XP Rabbit mAb Cell Signaling 19245
a-Tubulin (11H10) Rabbit mAb (HRP Conjugate) Cell Signaling 9099
b-Tubulin (9F3) Rabbit mAb Cell Signaling 2128
Biological Samples
Rat-adapted Nippostrongylus brasiliensis Sutherland et al., 2014 N/A
Chemicals, Peptides, and Recombinant Proteins
Collagenase B Roche 11088815001
Collagenase D Roche 11088866001
Pronase (Protease from Streptomyces griseus) Sigma P5147
DNase 1 Roche 10104159001
Recombinant mouse Amphiregulin BioLegend 554104
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant Mouse TGF-b1 BioLegend 763104
Recombinant Mouse IFN-g PeproTech 315-05
Recombinant Mouse IL-4 PeproTech 214-14
Recombinant Mouse IL-13 Immunotools 12340137
Recombinant Mouse IL-25 BioLegend 587304
Recombinant Mouse IL-33 PeproTech 210-33
Recombinant Mouse TSLP eBiosciences 34-8498-82
Lipopolysaccharides from Escherichia coli O111:B4 Sigma L4391
ATP Cytoskeleton BSA04-001
Gefitinib LC laboratories G-4408
U-73122 PLC inhibitor Cayman Chemical 70740
CWHM96/12 David W. Griggs lab N/A
ALK inhibitor SB431542 Abcam ab120163
Carbon Tetrachloride Sigma 87031
Brefeldin A Sigma B6542
Apyrase Sigma A6237
Evans blue Fluka Chemika 46160
Critical Commercial Assays
LIVE/DEAD Fixable Blue Dead Cell Stain Kit Thermo Fisher L23105
LEGENDplex Mouse/Rat Free Active/Total TGF-b1 Biolegend 740490
Experimental Models: Cell Lines
L929 The Francis Crick Institute Cell Services N/A
Experimental Models: Organisms/Strains
Areg/ Luetteke et al., 1999 N/A
Myd88/ 3 Trif/ Yamamoto et al., 2003; Adachi et al., 1998 N/A
Rag1/ Mombaerts et al., 1992 N/A
Aregflox/flox The European Conditional Mouse
Mutagenesis Program
Aregtm2a(EUCOMM)Hmgu
LysM-cre+/ Clausen et al., 1999 N/A
Vav1-cre+/ de Boer et al., 2003 N/A
Egfrflox/flox Natarajan et al., 2007 N/A
Itgavflox/flox Foo et al., 2006 N/A
Pdgfrb-cre+/ Foo et al., 2006 N/A
Pdgfrb-BAC-eGFP Henderson et al., 2013 N/A
Oligonucleotides
Acta2 Applied Biosystems Mm00725412_s1
Col1a1 Applied Biosystems Mm00801666_g1
Col3a1 Applied Biosystems Mm01254476_m1
Areg Applied Biosystems Mm00437583_m1
Pdgfrb Applied Biosystems Mm00435553_m1
Rn18s Applied Biosystems Mm03928990_g1
Gapdh Applied Biosystems Mm99999915_g1
Itgav Applied Biosystems Mm00434486_m1
Software and Algorithms
FlowJo 10 FLOWJO, LLC https://www.flowjo.com/
Prism 7 GraphPad Software https://www.graphpad.com/scientific-
software/prism/
Other
ALZET osmotic minipumps Charles River 1007D
The MouseOxTM Pulse-oximeter Starr Life Sciences N/A
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CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dietmar
Zaiss (dietmar.zaiss@ed.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Breeding of Experimental Animals
Areg/ (Luetteke et al., 1999; Zaiss et al., 2006), Aregflox/flox (Aregtm2a(EUCOMM)Hmgu obtained from The European Conditional Mouse
Mutagenesis Program), Vav1-cre+/ (de Boer et al., 2003), Lyz2cre+/ (Clausen et al., 1999), Pdgfrb-cre+/ (Foo et al., 2006; Hender-
son et al., 2013), Egfrflox/flox (Natarajan et al., 2007), Itgavflox/flox (Foo et al., 2006; Henderson et al., 2013), Pdgfrb-BAC-eGFP
(Henderson et al., 2013) reporter mice, as well as Myd88/ 3 Trif-/ (Adachi et al., 1998; Yamamoto et al., 2003), and Rag1/
(Mombaerts et al., 1992) were bred and maintained on a C57BL/6 background at the University of Edinburgh under specific-
pathogen free conditions. Mice were 8–12 weeks old at the start of the experiments and were housed in individually ventilated cages.
Mice were not randomized in cages, but each cage was randomly assigned to a treatment group. Investigators were not blinded to
mouse identity during necropsy but during worm counts and histological analysis. Male and female mice were used to perform the
experiments. However, in no occasion, we observed an obvious difference between sexes within the parameters analyzed for our
experiments. Experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986.
The UK Home Office accredited all researchers for animal handling and experimentation. Dispensation to carry out animal research
at the University of Edinburgh was approved by the University of Edinburgh Animal Welfare and Ethical Review Body and granted by
the UK government Home Office; as such all research was carried under the project license PPL70/8470. Sample sizes were based
on extensive previous experience with Nippostrongylus brasiliensis infection model. No individual data points were excluded under
any circumstances.
METHOD DETAILS
Primary Cell Isolation
Lung
Mouse lungs were perfused through the left ventricle using cold Hanks’ Balanced Salt Solution (Sigma). The lung was excised,
minced with scissors and further digested in 0.1% Collagenase B, 1% Pronase and 0.025% DNase 1 (Roche). After addition of
the enzymes the tissues were incubated at 37 C for 20 min and forced through a 70 mMcell strainer. The cell suspension was centri-
fuged twice at 200g for 5 min. Following staining detailed in ‘‘Flow Cytometry’’, pericytes were sorted using a FACSAria (BD
Biosciences).
Liver
Pericyte isolation frommouse liverswere carried out as described in (Graham, 2002). Briefly, livers from 4micewere harvested in cold
Hanks’ Balanced Salt Solution post perfusion. Organs were minced, enzyme digested and filtered in a similar way to the lungs. The
suspension was centrifuged at 600g for 7 minutes at room temperature. A gradient was prepared using 60% Optiprep (Alere) with
HBSS in the lower phase and 39.86% Optiprep in the middle phase homogenised with the cell pellet. The top was layered with
0.5 ml HBSS followed by centrifugation at 1400g for 20 minutes at 4C without break. The interphase between the top and middle
layers were collected and washed by centrifugation at 600g for 7minutes. Finally, the pellet was treated with RBC lysis buffer (Sigma)
and washed. Cells were isolated and plated in tissue culture treated 12 well plates (Corning) in pericyte medium i.e., DMEMwith 20%
FBS, 10mM L-Glutamine, 100units Penicillin Streptomycin (Gibco) and were allowed to settle overnight at 37C, in humidified atmo-
sphere at 5% CO2. The cells were then washed thoroughly with PBS and then treated as indicated.
Pericyte Culture Conditions and Treatment
Pericytes were cultured in DMEM containing glucose, pyruvate and L-glutamine (Gibco), supplemented with penicillin-streptomycin,
5 x10-5 M 2-mercaptoethanol (Sigma) and 15% FCS (Gibco) at 37C in a humidified atmosphere at 5% CO2. Isolated pericytes were
incubated in the presence of 50-100 ng/mL of AREG (BioLegend) or 0.5 ng/mL of TGF-b1 (R&D Systems). Inhibitors were used at the
following concentrations: Gefitinib (LC laboratories) (1 mM), U-73122 (1 mM), CWHM12 (2 mM) and Alk5i (1 mM). CWHM-96 the
inactive enantiomer of CWHM-12 was used as control. Under these conditions, cell viability was higher than 92%. After 16 hours
of culture, cells were stored in TRIzol (Invitrogen) and supernatants were frozen for subsequent analysis. For the analysis of the
expression of aSMA by WB, cells were cultured for 24 hours.
TGF-b Latent Associated Protein (LAP) Binding Assay
Activation of integrin-aV was quantified as described before (Munger et al., 1999). In summary, pericytes in suspension were treated
with 50-100 ng/mL rAREG for 0–30 min in the presence or absence of a blocking antibody against integrin-aV (clone RMV-7, 1 mg/ml)
and subsequently with 0.1 mg/ml recombinant mouse LAP (Biolegend) for 30 min at 37 C. After fixation and washing, cells were
stained with an anti-LAP and analyzed by flow cytometry.Immunity 50, 645–654.e1–e6, March 19, 2019 e3
Macrophage Culture Conditions and Treatment
Bonemarrow-derivedmacrophages (BMDMs) fromWTmicewere differentiated from bonemarrow precursors. Briefly, bonemarrow
cells were isolated and propagated for 7 days in RPMI (Gibco) containing 20% FCS (Sigma-Aldrich), 30% L929 conditioned media
and 1% Pen/Strep (Gibco).
Alveolar macrophages were obtained from the bronchoalveolar lavage (BAL) of mice with Dulbecco’s phosphate buffered saline
with 0.5%BSA (m/v). Peritoneal macrophages were obtained frommice by washing the peritoneal cavity with RPMI 1640 containing
2 mM L-glutamine, 200U/ml penicillin, 100 mg/ml streptomycin. Cells were separated from the lavage fluid by centrifugation (250 x g,
5 min), resuspended in RPMI 1640 medium (5% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, supplemented
with 2 mM glutamine), and purified by adherence. Viability of adherent cells was assessed by trypan blue exclusion test. Flow cytom-
etry analysis determined that at least 90%of adherent cell weremacrophages. Subsequently, cells were treated with LPS, IFNg, IL-4,
IL-13, IL-25, IL-33, TSLP (100 ng/ml) and ATP (10 mM). After 10 hours of culture, cells were stored in TRIzol for subsequent analysis.
Co-cultures of Macrophages and Pericytes
Alveolar macrophages were obtained from naı¨ve and N. brasiliensis-infected mice as described above. After purification, macro-
phages were cultured for 24 h in DMEM containing glucose, pyruvate and L-glutamine, supplemented with penicillin-streptomycin,
5 x10-5 M 2-mercaptoethanol and 15% FCS. After which FACS-sorted pericytes were added 1:50 and cultured for another 16 hours.
Alternatively, the supernatant of the macrophages was used to culture primary pericytes.
Measurement of Bioactive TGF-b
Luciferase Assays
Bioactive TGF-b was measured in the supernatants of liver pericyte cultures using transgenic Mink Lung Epithelial cells (MLECs),
which express luciferase, downstream of the (PAI-1) promoter, corresponding to the expression of bioactive TGF-b (Abe et al.,
1994). The assay was carried out as described in (Wipff et al., 2007). In brief, MLECs were plated as 25,000/ well and allowed to
adhere for 3 hours following which their supernatant was replacedwith either TGF-b standards, or the pericyte supernatant from con-
trol or treated wells. Measurement of total TGF-b was achieved by heat activation of the samples. After 20 hours of incubation, the
MLECs were lysed and were read for luciferase activity using the Varioscan Flash (Thermo Scientific). Data were represented as a
percentage of the total TGF-b in the respective sample.
FACS-based ELISA
Alternatively, active and total TGF-b1 were measured in culture supernatants using ELISA kits (Biolegend) as per manufacturer’s
instructions.
Nippostrongylus brasiliensis Infection and Delivery of Recombinant AREG and TGF-b1
Rat-adapted N. brasiliensis was maintained by serial passage through Sprague Dawley rats, as described previously (Sutherland
et al., 2014). Mice were infected subcutaneously with 300 N. brasiliensis third-stage larvae and 500 larvae for SpO2 measurements.
Analysis of samples was performed at different times post infection, as indicated. Adult worm burden was determined by removing
the small intestine and exposing the lumen by dissection. The lungs were washed with Dulbecco’s phosphate buffered saline to
obtain the bronchoalveolar lavage (BAL) before tissue collection. Subsequently, the right lung was fixed for histology analysis. Alter-
natively, one section of the left lung was stored in TRIzol for mRNA quantification; another section was homogenized to obtain single
cell suspensions for flow cytometry analysis, and a third section was stored for western blot analysis. In this case, lung tissue was
homogenized in lysis buffer.
In rAREG and rTGF-b1 delivery experiments, 5 mg of either mouse recombinant protein (BioLegend) were injected intraperitoneally
(AREG) or via the tail vein (TGF-b1) at days 1, 2 and 3 post N. brasiliensis infection following procedures described previously
(Jamieson et al., 2013; Monticelli et al., 2011).
Liver Injury
Carbon tetrachloride liver injury was induced by injecting i.p. with 0.5 ml/g body weight CCl4 (Sigma-Aldrich) in a 1:1 ratio in olive oil
(Sigma) or olive oil alone for a control group. Livers were harvested at specific time points post injection, as indicated. For the analysis
of different parameters, the liver was first perfused in situ by injecting ice cold PBS (Sigma) through the hepatic portal vein and gently
cutting the inferior vena cava to release the pressure built up of blood. Different lobes of the liver were collected for cell isolation, qRT-
PCR and histology. The lobes used for different readouts were consistent across all experiments.
Evans Blue Dye Leakage Assays
Evans Blue leakage assays were performed as described before (Goto et al., 2010): mice were injected via the tail vein with Evans
Blue dye (Fluka) (100 mg/kg) four days after N. brasiliensis infection or three days after CCl4-induced liver injury. Three hours after
Evans Blue injection, BAL was performed and alveolar cells were removed by centrifugation. Alternatively, the livers were perfused,
removed, and immersed in formamide at 55C. After 24 hours’ incubation, formamide including eluted blue dye was collected. The
absorbance at 650 nm was measured with BAL fluid and formamide samples.e4 Immunity 50, 645–654.e1–e6, March 19, 2019
In Vivo Delivery of Brefeldin A and Apyrase
Apyrase treatment was performed by intravenous administration of 25 U apyrase (Sigma-Aldrich) 24 and 32 hours prior to harvest.
In vivo delivery of brefeldin A was performed as previously described (Minutti et al., 2017a). In brief, brefeldin A (Sigma) was resus-
pended at 20 mg/ml in DMSO. Further dilution to 1mg/ml wasmade in PBS, and 200 ml were injected intravenously 6 hours later BAL
and lung tissue were harvested and processed in the presence of Monensin (Sigma) for flow cytometry analysis.
In Vivo CWHM 12 Delivery
CWHM 12 and CWHM-96, the inactive control enantiomer of CWHM-12, were prepared as reported previously (Henderson et al.,
2013). CWHM 12 and CWHM 96 were solubilized in 50% DMSO (in sterile water) and dosed to 100 mg per kg body weight per
day. Drug or vehicle (50% DMSO) was delivered by implantable ALZET osmotic minipumps (Charles River). Pumps were inserted
subcutaneously 3 days before N. brasiliensis infection. Delivery of CWHM 96 or vehicle (DMSO/H2O) produced indiscernible effects.
Measurement of Pulse Oximetry
The MouseOxTM Pulse-oximeter (Starr Life Sciences) was used to measure blood SpO2 and breathe rate in N. brasiliensis-infected
mice during the course of infection. A depilatory agent (Nair, Church & Dwight) was applied to the neck of mice a day prior to
N. brasiliensis infection to remove hair and delay future hair growth. For readingsmice were sedated with 2.5-5mg/kg intra-peritoneal
Midazolam (Roche). Subsequently, the oximeter clip was placed on the neck and percent SpO2 was measured each second over
several minutes, data shown is the ratio of SpO2/breathe rate readings recorded over 3–5 min per mouse.
Histology
Lung and liver lobes were fixed with 10% neutral buffered formalin (lungs were inflated with fixative agent), incubated overnight and
transferred to 70% ethanol. Organs were paraffin-embedded, sectioned and stained with hematoxylin and eosin (H&E) and Periodic
acid–Schiff (PAS). The following morphological changes within the lungs were graded - Alveolar wall destruction: 0 absent, 1 mild
damage, 2 moderate, 3 severe; Peri-bronchial/peri-vascular mononuclear cell infiltrate and Peri-bronchial/peri-vascular neutrophil
infiltrate: 0 absent, 1 <20% bronchi/vessel involvement, 2 20%–70% involvement, 3 >70% involvement; Alveolar neutrophils: 0 ab-
sent, 1 mild increase in neutrophils, 2 moderate, 3 severe). Alternatively, livers were graded according to the following criteria:
Necrosis 0 no pathological change, 1 degenerated hepatocytes with only rare foci of necrosis, 2 small area of mild centrilobular
necrosis around the central vein, 3 area of mild centrilobular necrosis severer than grade 2, 4 centrilobular necrosis severer than
grade 3. Inflammation 0 none, 1 isolated inflammatory cells, >10% central vein profiles, 2 diffuse individual and aggregates of peri-
central inflammatory cells, 3 confluent pericentral inflammation, <50% circumference, 4 confluent pericentral inflammation, >50%
circumference. The degree of organ injury and inflammation was assessed by the sum of scores of the parameters, and the average
sum of each was compared between groups.
RNA Extraction and Quantitative Real-Time PCR
Tissue or cells in culture were homogenised in TRIzol with a TissueLyser (Qiagen) and RNA was isolated following manufacturer’s
instructions. Reverse transcription was performed using 1 mg of total RNA using 200 U of M-MLV reverse transcriptase, 10 mM
dNTPs, and 0.5 mg Oligo dT15 and RNasin inhibitor (Promega). Transcript levels of genes of interest were measured by real-time
PCR with the Lightcycler 480 II system (Roche) using Taqman Master kit and specific primers (STAR Methods; Table S1), as previ-
ously described. PCR amplification was analysed using 2nd derivative maximum algorithm (LightCycler 480 Sw 1.5, Roche) and the
expression of the gene of interest was normalised to the housekeeping gene Rn18s.
Western Blots
Tissue or cell lysates were prepared by homogenization in a buffer containing: 10 mM HEPES (pH 7.9), 15 mM MgCl, 10 mM KCl,
0.5 mM EDTA, 0.2% Triton X-100, 1 mM benzamidine, 200 mg/ml aprotinin, 200 mg/ml leupeptin, 1 mM PMSF (Sigma-Aldrich)
and phosphatase inhibitors: 20 mM b-glycerophosphate, 10 mM NaF, 10 mM sodium pyrophosphate, and 2 mM orthovanadate
(Sigma-Aldrich). Tissue lysates were resolved by 8% (m/v) SDSPAGE in reducing conditions and transferred to nitrocellulose
membranes. After blocking with 2% BSA, membranes were washed and incubated with an anti-pSMAD3, aSMA or a/b-Tubulin
antibodies (Cell Signaling) overnight at 4C. Proteins were detected with secondary Abs goat anti-mouse A680 (Life Technologies)
and goat anti-rabbit IR800 (Thermo scientific) and visualized with an infrared imaging system (Odyssey; LI-COR Biosciences).
Flow Cytometry
Single cell suspensions from lung or liver lobes were prepared by digesting with 0.03% Collagenase D, 0.038% Collagenase B and
0.025% DNase 1 (Roche) in HBSS at 37C for 20 minutes. Tissue was homogenized by forcing through a 70 mM cell strainer and
subsequently treated with red blood cell lysis buffer (Sigma). Red blood cells and other tissue and BAL cells were counted using
an automated cellometer T4 (Peqlab). Cells were incubated with Fc block (CD16/CD32 and mouse serum) (BD Biosciences) and
stained with fluorescent conjugated antibodies against different cell surface antigens (STAR Methods) or isotype control, in some
cases followed by secondary reagents (Invitrogen). Different cell populations were identified by the expression of markers as shown
in Figure S3. Following surface staining, cells were fixed with 2% paraformaldehyde in Dulbecco’s phosphate buffered saline for
20min at room temperature, permeabilized with Permwash (BDBiosciences), and then stainedwith anti- amphiregulin, anti- RELMa,Immunity 50, 645–654.e1–e6, March 19, 2019 e5
or isotype control followed by secondary reagents (Invitrogen). For detection of Ki67 and FoxP3, cells were stained for surface
markers, then fixed and permeabilized using FoxP3 staining buffer set (eBioscience), and subsequently stained with FoxP3 or
Ki67 set. Expression of amphiregulin, RELMa and Ki67 was determined relative to isotype control staining. Live/Dead (Life Technol-
ogies) was used to exclude dead cells from analysis. Samples were analyzed by flow cytometry using Becton-Dickinson FACS LSR II
and FlowJo software.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical evaluation of different groups was performed either by analysis of variance (ANOVA) followed by the Tukey multiple
comparison test or by non-parametric Mann-Whitney test, as indicated. An a level % 5% (p % 0.05) was considered significant.
All statistical calculations were performed using PRISM (Graphpad).
DATA AND SOFTWARE AVAILABILITY
All data are available in the manuscript or the Supplemental Information.e6 Immunity 50, 645–654.e1–e6, March 19, 2019
